

GILEAD SCIENCES: INVESTING IN AMERICA'S HEALTH AND ECONOMIC LEADERSHIP

WHERE MEDICINES ARE MADE MATTERS

Gilead is an American-born, U.S.-based biopharmaceutical company with a 37-year history of commitment to domestic innovation, job creation, and economic growth. With \$32 billion in planned U.S. investments through 2030, Gilead is building more than medicines—also helping build the infrastructure of public health, resilience, and global leadership.

A PROVEN ECONOMIC ENGINE, ROOTED IN THE U.S.

Gilead's growth strategy is anchored in the U.S. From tax contributions and job creation to research and reinvestment, our footprint strengthens the American economy and innovation ecosystem.

Delivering Innovation for Today and Tomorrow

AMERICA'S SCIENCE, BUILT TO SERVE THE WORLD.

Gilead's R&D teams are at the forefront of medical breakthroughs. Our domestic research and manufacturing drive therapies that protect patients today and prepare the country for future health threats.

Science That Anticipates What's Next

Gilead is advancing innovative therapies in HIV, oncology, inflammation and virology — building platforms that can adapt to emerging health challenges and evolving patient needs.

Leadership in HIV, biologics and cell therapy

Gilead has created more than a dozen HIV therapies, pioneered single-tablet regimens and is advancing patient-centered medicine through U.S.-based innovation.

Future-Ready Facilities

New state-of-the-art labs and manufacturing sites will accelerate therapy development and prepare for future public health needs.

KEY FACTS

**\$32 billion committed
to U.S. innovation
through 2030**

**\$43 billion in projected
U.S. economic value
from \$32B investment**

**~10,800 high-quality
U.S. jobs**

**98% of R&D
infrastructure
located in the U.S.**

**Over 80% of global
profits recognized
in the U.S.**

**~\$2.7 billion in
U.S. federal
and state taxes in 2025**

Built Here. Invested Here. Leading Here.

OUR COMMITMENT TO THE U.S. ISN'T SYMBOLIC. IT'S STRUCTURAL.

Nearly every part of Gilead's business is embedded in the U.S. economy. We believe the best way to protect public health, fuel scientific discovery and grow jobs is to build where it matters most.

Commitment to Community

INVESTING IN COMMUNITIES AND LEADING THE FIGHT AGAINST HIV

Since 2020, Gilead has contributed more than \$1 billion to charitable causes across the United States. In 2024, the company was recognized by Funders Concerned About AIDS as the #1 funder of U.S. HIV-related programs for the third consecutive year.